{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:26:38Z","timestamp":1778610398314,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.eururo.2012.11.032","type":"journal-article","created":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T21:01:13Z","timestamp":1353531673000},"page":"994-1002","source":"Crossref","is-referenced-by-count":30,"title":["Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial"],"prefix":"10.1016","volume":"64","author":[{"given":"Andrew","family":"Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotirios G.","family":"Stergiopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Mietlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2012.11.032_bib0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.11.032_bib0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2012.11.032_bib0015","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2004.07.960","article-title":"Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST","volume":"22","author":"Ratain","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.11.032_bib0020","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ejca.2011.11.018","article-title":"Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine","volume":"48","author":"Krajewski","year":"2011","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2012.11.032_bib0025","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2011.0124","article-title":"NCCN task force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy","volume":"9","author":"Hudes","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2012.11.032_bib0030","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1464-410X.2011.10629.x","article-title":"Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials","volume":"108","author":"Coppin","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.11.032_bib0035","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.11.032_bib0040","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/sj.bjc.6605567","article-title":"Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib","volume":"102","author":"van der Veldt","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2012.11.032_bib0045","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.ejca.2012.01.027","article-title":"Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study","volume":"48","author":"Oudard","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2012.11.032_bib0050","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/annonc\/mdp466","article-title":"Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib","volume":"21","author":"Thiam","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2012.11.032_bib0055","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/jnci\/djm158","article-title":"Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small-cell lung cancer","volume":"99","author":"Karrison","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.11.032_bib0060","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1200\/JCO.2008.21.0807","article-title":"Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics","volume":"27","author":"Claret","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.11.032_bib0065","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/clpt.2009.64","article-title":"Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development","volume":"86","author":"Wang","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eururo.2012.11.032_bib0070","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/annonc\/mdr350","article-title":"The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy","volume":"23","author":"Suzuki","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2012.11.032_bib0075","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.eururo.2011.01.038","volume":"59","author":"Krajewski","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.11.032_bib0080","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.hoc.2011.04.003","article-title":"Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far","volume":"25","author":"Tang","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2012.11.032_bib0085","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.2011-S2-04","article-title":"Tumor biology and prognostic factors in renal cell carcinoma","volume":"16","author":"Finley","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2012.11.032_bib0090","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2011.06.041","article-title":"Prognostic factors and predictive models in renal cell carcinoma: a contemporary review","volume":"60","author":"Sun","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.11.032_bib0095","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2012.11.032_bib0100","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jnci\/86.11.829","article-title":"Dangers of using \u201coptimal\u201d cutpoints in the evaluation of prognostic factors","volume":"86","author":"Altman","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.11.032_bib0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of changepoint methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Comput Stat Data Anal"},{"key":"10.1016\/j.eururo.2012.11.032_bib0110","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.25750","article-title":"Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy","volume":"117","author":"Heng","year":"2011","journal-title":"Cancer"},{"issue":"Suppl 15","key":"10.1016\/j.eururo.2012.11.032_bib0115","article-title":"Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) [abstract 4525]","volume":"28","author":"Halabi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.11.032_bib0120","unstructured":"Oudard S, Escudier B, Hutson TE, et al. Everolimus in patients with metastatic renal cell carcinoma (mRCC): subgroup analysis of patients with a reduction in tumor burden enrolled in a randomized, placebo-controlled, phase 3 trial. Paper presented at: 26th Annual European Association of Urology Congress; March 18\u201322, 2011; Vienna, Austria."},{"key":"10.1016\/j.eururo.2012.11.032_bib0125","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2012.11.032_bib0130","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1158\/1078-0432.CCR-10-1279","article-title":"Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?","volume":"16","author":"LoRusso","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"10.1016\/j.eururo.2012.11.032_bib0135","article-title":"Clinical importance of including new and nontarget lesion assessment of disease progression (PD) to predict overall survival (OS): implications for randomized phase II study design [abstract 2543]","volume":"30","author":"Mietlowski","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812014078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812014078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T07:23:04Z","timestamp":1540106584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283812014078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0302283812014078"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2012.11.032","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}